We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Optical Methodology for Detection of COVID-19 Beats RT-PCR in Speed and Sample Size

By LabMedica International staff writers
Posted on 21 Feb 2022
Print article
Image: Researchers working on the project (Photo courtesy of University of Seville)
Image: Researchers working on the project (Photo courtesy of University of Seville)

An optical methodology for the rapid detection of COVID-19 provides an advantage over PCR in terms of the speed of sample processing and the ability to simultaneously analyze a large number of samples.

The new methodology developed by researchers at the University of Seville (Seville, Spain) has obtained a sensitivity of 100% and a specificity of 87.5% in the detection of SARS-CoV-2 in nasopharyngeal exudate (the same samples used in a PCR test) from symptomatic people. It has also been possible to detect the presence of SARS-CoV-2 in fresh saliva of asymptomatic people, as well as to detect, differentiate and quantify two types of synthetic viruses (lentiviruses and synthetic coronaviruses) in two biofluids (saline solution and artificial saliva).

The new methodology allows for the detection of viruses in liquid droplets and dry residues deposited on surfaces, through hyperspectral imaging and data processing based on advanced statistics and artificial intelligence. It allows rapid processing of multiple samples simultaneously, without contact or reagents and with relatively simple equipment, usable by personnel with minimal training. The new technique uses standard optical equipment and has been developed so that it can be implemented in resource-constrained settings.

However, the researchers have warned that these results should still be viewed with caution, as they constitute a 'proof of concept', with relatively small numbers of cases, under partially controlled laboratory conditions. For this reason, they are currently working on validating this new methodology under generic conditions, including new variants of the virus and the effects of vaccines.

Related Links:
University of Seville 

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.